Intervention not reported
5‐year OS (stage III) · women with stage III or IV endometrial cancer after primary cytoreductive surgery
The intervention showed no clear difference in 5‐year OS (stage III) (moderate certainty).
1 finding from 1 review
Intervention not reported
5‐year PFS (stage III) · women with stage III or IV endometrial cancer after primary cytoreductive surgery
The intervention showed no clear difference in 5‐year PFS (stage III) (moderate certainty).
1 finding from 1 review
Intervention not reported
PFS (stage III/IV) Median · women with advanced (stage III/IV) endometrial cancer after surgery and radiotherapy
The intervention showed no clear difference in PFS (stage III/IV) Median (moderate certainty).
1 finding from 1 review
Intervention not reported
Lymph node mets analysis ‐ N+ OS · patients with resectable gastric cancer
The intervention probably leads to lower lymph node mets analysis ‐ N+ OS (moderate certainty).
1 finding from 1 review
Intervention not reported
Stage OS analysis ‐ T1/2 OS · patients with resectable gastric cancer
The intervention showed no clear difference in stage OS analysis ‐ T1/2 OS (moderate certainty).
1 finding from 1 review
Intervention not reported
Stage OS analysis ‐ T3/4 OS · patients with resectable gastric cancer
The intervention showed no clear difference in stage OS analysis ‐ T3/4 OS (moderate certainty).
1 finding from 1 review
Intervention not reported
Lymph node mets analysis ‐ N‐ OS · patients with resectable gastric cancer
The intervention showed no clear difference in lymph node mets analysis ‐ N‐ OS (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality (after 3 years) · Patients with refractory/relapsed Hodgkin lymphoma
The intervention showed no clear difference in mortality (after 3 years) (moderate certainty).
1 finding from 1 review
Intervention not reported
Relapse or death (at 3 years) · Patients with refractory/relapsed Hodgkin lymphoma
The intervention probably leads to lower relapse or death (at 3 years) (moderate certainty).
1 finding from 1 review
Intervention not reported
Treatment‐related mortality ‐ overall analysis (at 3 years) · Patients with refractory/relapsed Hodgkin lymphoma
The intervention showed no clear difference in treatment‐related mortality ‐ overall analysis (at 3 years) (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events not estimable · Patients with refractory/relapsed Hodgkin lymphoma
1 finding from 1 review
Intervention not reported
Quality of life not reported · Patients with refractory/relapsed Hodgkin lymphoma
1 finding from 1 review
Participant‐rated global improvement · people with chronic plaque psoriasis
1 finding from 1 review
Percentage of participants reaching PASI 75 · People with palmoplantar psoriasis
1 finding from 1 review
Withdrawals due to adverse events · People with palmoplantar psoriasis
1 finding from 1 review
Clearance rate · People with palmoplantar psoriasis
NB‐UVB showed no clear difference in clearance rate compared with topical PUVA (low certainty).
1 finding from 1 review
Participant‐rated global improvement · People with chronic plaque or guttate psoriasis
1 finding from 1 review
Percentage of participants reaching PASI 75 · People with chronic plaque or guttate psoriasis
NB‐UVB plus retinoid showed no clear difference in percentage of participants reaching PASI 75 compared with PUVA plus retinoid (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · People with chronic plaque or guttate psoriasis
1 finding from 1 review
Clearance rate · People with chronic plaque or guttate psoriasis
NB‐UVB plus retinoid showed no clear difference in clearance rate compared with PUVA plus retinoid (low certainty).
1 finding from 1 review